Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1726 • ACR Convergence 2025
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Xingxing Zhu¹, yue Yu¹, Yangfen Li¹, Panwen wang², ying li², Chantal McCabe², shiju chen², Brenna Sharp², Amber Wolzen², Hannah Langenfeld¹, Andrew C. Hanson¹, Cynthia Crowson³, svetomir Markovic², John Davis¹, Haidong Dong², Uma Thanarajasingam¹ and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: The immunological basis of inflammatory arthritis (IA) immune related adverse event (irAE) following anti-PD-1/PD-L1 immune checkpoint inhibition (ICI) therapy is incompletely understood. The relationship…
Abstract Number: 1656 • ACR Convergence 2025
Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis
Jiha Lee¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Michigan, Ann Arbor, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In older adults with rheumatoid arthritis (RA), anti-TNF therapies are typically used as first-line biologic treatment. However, many patients require a switch to non-TNF…
Abstract Number: 1366 • ACR Convergence 2025
Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
Rémi Marty¹, Baran Ufuktepe², Nicola Tilt³, Flore Decuypere⁴, Angela Blake³, Sandeep Kiri³ and Mohammed Soomro³, ¹UCB Pharma, Brussels, Belgium, Anderlecht, Belgium, ²UCB Pharma Istanbul, Turkey, istanbul, Turkey, ³UCB Pharma, Slough, United Kingdom, Slough, United Kingdom, ⁴UCB Pharma Brussels, Belgium, Brussels, Belgium
Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA), the presence of rheumatoid factor (RF), particularly at high levels, is…
Abstract Number: 1348 • ACR Convergence 2025
Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Rieke Alten¹, Gerd Burmester², Marco Matucci-Cerinic³, Jens Gerwien⁴, Walid Fakhouri⁴, Samuel Ogwu⁴, Ewa Haladyj⁴, Inmaculada De La Torre⁴, Bruno Fautrel⁵ and AJ Fernandez⁴, ¹SCHLOSSPARK KLINK, Teaching Hospital of University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³University San Raffaele Milano, Milano, Milan, Italy, ⁴Eli Lilly and Company, Indiana Polis, IN, ⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Here, we provide descriptive baseline characteristics and effectiveness outcomes of Baricitinib (BARI) and other ts/bDMARDs at 24-month (24M) in both European (EU) and non-European…
Abstract Number: 1331 • ACR Convergence 2025
Anti-beta-2-glycoprotein-1 IgA antibodies facilitate macrophage cholesterol loading and influence coronary atherosclerosis progression in a dose-dependent manner in rheumatoid arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Changes in serum cholesterol loading capacity (CLC) on macrophages were linked to coronary plaque progression in rheumatoid arthritis (RA). Inflammation, LDL oxidation and autoantibodies…
Abstract Number: 1315 • ACR Convergence 2025
High-resolution thermography and Artificial Intelligence to evaluate and classify Rheumatoid Arthritis
Kale Mayor¹, Joey Mercier¹, Yuxi Long², David Robinson¹, Pingzhao Hu², Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Western University, London, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune polyarthritis that typically affects the small joints of the hands and feet. While imaging modalities such as ultrasound…
Abstract Number: 1228 • ACR Convergence 2025
Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Brennan Spiegel¹, Jeffrey Curtis², Yashar Eshraghi³, Maged Guirguis³, Beth Darnall⁴, Christine Rini⁵, Emily Holladay⁶, Mehra Muskaan¹, So Yung Choi¹ and Samuel Eberlein¹, ¹Cedars Sinai, Los Angeles, CA, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³University of Queensland Ochsner Medical School, New Orleans, LA, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵Northwestern University, Chicago, IL, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Evidence-based behavioral treatments for chronic pain are largely inaccessible, particularly to rural patients. This decentralized randomized controlled trial compared the effectiveness of two digital,…
Abstract Number: 1065 • ACR Convergence 2025
Age of Disease Onset and Risk of Serious Infection with anti-TNF Use in Older Adults with Rheumatoid Arthritis
Jiha Lee¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Michigan, Ann Arbor, MI, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Older age is a recognized risk factor for serious infection (SI) associated with anti-TNF therapy in rheumatoid arthritis (RA). Among older adults with RA,…
Abstract Number: 1005 • ACR Convergence 2025
CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
Yusuke Miyashita¹, Yang Yang², Madison Mangin³, Maryrose Hahn² and Margaret Chang², ¹Boston Children's Hospital, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease featured with recurrent inflammation in the same joints, a characteristic termed joint-specific memory. We previously demonstrated…
Abstract Number: 0905 • ACR Convergence 2025
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Jinyang Li, Xiu Han, Yi Wang, Yiyi Li, Zhaoru Ma, Yang Li, Zhimin Zhang, Liu Li, Meng Ni, Jiangkun Bi, Xing Yang, Yao Xiong, Shuaixiang Zhou and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Immune reset, achieved through profound and sustained depletion of B cells and/or plasma cells, has demonstrated significant clinical efficacy in patients with severe and…
Abstract Number: 0816 • ACR Convergence 2025
Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs
Andreas Kerschbaumer¹, Marlene Steiner², William H. Robinson³, Josef Smolen⁴ and Daniel Aletaha⁵, ¹Stanford University / Medical University of Vienna, Stanford, CA, ²Medical University of Vienna, Vienna, Wien, Austria, ³Stanford University, Palo Alto, CA, ⁴Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Joint swelling and tenderness are clinical hallmarks of rheumatoid arthritis (RA) and central to disease assessment. Regardless of treatment type, stringent remission based on…
Abstract Number: 0502 • ACR Convergence 2025
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Satani Sharkas¹, Saeed Abughazaleh² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Boston Medical Center - Brighton, Brighton, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are approved treatments for rheumatoid arthritis (RA). However, comparative safety data on cardiovascular outcomes and all-cause mortality…
Abstract Number: 0484 • ACR Convergence 2025
Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Ernest Choy¹, Marco Gattorno², Kamila Klama³, Andras Illes⁴, Peter Baker⁵, Maria Romanova Michailidi⁶ and Anna Zubrzycka-Sienkiewicz⁷, ¹Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ²IRCCS G. Gaslini, Genova, Genoa, Italy, ³Solumed Clinical Research Center, Poznan, Poland, ⁴Fresenius Kabi SwissBioSim, Eysin, Switzerland, ⁵Fresenius Kabi Biopharma, Eysins, Switzerland, ⁶University of Geneva, Eysins, Switzerland, ⁷Reumatika - Centrum Reumatologii, Warszawa, Poland
Background/Purpose: Biosimilars offer comparable efficacy and safety to their originators, thereby improving patient access to affordable treatments. FK-Tocilizumab (FK-toci) is the first tocilizumab biosimilar approved…
Abstract Number: 0468 • ACR Convergence 2025
Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis (ERS-RA) in a nationwide multicenter Chinese cohort
Xingbei Dong¹, Nan Jiang², Hong Li³, Misti Paudel⁴, Jiangmei Liu⁵, Xinwang Duan⁶, Dongmei Wu⁷, Hongbin Li⁸, Fen Li⁹, Yongfu Wang¹⁰, Ju Liu¹¹, Shengqian Xu¹², Hui Luo¹³, huanzi dai¹⁴, Shuhong Chi¹⁵, Jian Xu¹⁶, Lijun Wu¹⁷, zhaohui zheng¹⁸, Jing Xue¹⁹, Xiaofu Yu²⁰, QIn Huang²¹, Xiaofei Shi²², Xiaomin Zhang²³, Yuehong Huo²⁴, Qian Wang², Xiaofeng Zeng²⁵, Daniel Solomon²⁶, Mengtao Li² and Xinping Tian², ¹Peking Union Medical College Hospital, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ³Beijing Anzhen Hospital, Capital Medical University, Beijing, China (People's Republic), ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Chinese Center for Disease Control and Prevention, Beijing, China (People's Republic), ⁶The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷The People's Hospital of Yuxi City, Yuxi, China (People's Republic), ⁸The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ⁹The Second Xiangya Hospital of Central South University, Changsha, China (People's Republic), ¹⁰The First Affiliated Hospital of Baotou Medical College, Baotou, China (People's Republic), ¹¹Affiliated Jiujiang Hospital of Nanchang University, Jiujiang, China (People's Republic), ¹²The First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), ¹³Xiangya Hospital of Central South University, Changsha, China (People's Republic), ¹⁴Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic), ¹⁵General Hospital of Ningxia Medical University, Yinchuan, China (People's Republic), ¹⁶The First Affiliated Hospital of Kunming Medical University, Kunming, China (People's Republic), ¹⁷People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China (People's Republic), ¹⁸Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), ¹⁹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), ²⁰Guyuan People’s Hospital, Guyuan, China (People's Republic), ²¹Nanfang Hospital, Guangzhou, China (People's Republic), ²²The First Affiliated Hospital of Henan University of science and Technology, Luoyang, China (People's Republic), ²³Red Flag Hospital Affiliated to Mudanjiang Medical College, Mudanjiang, China (People's Republic), ²⁴The Fifth People's Hospital of Datong, Datong, China (People's Republic), ²⁵Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ²⁶Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular (CV) events compared to the general population. However, this risk is often…
Abstract Number: 0451 • ACR Convergence 2025
Menopause Status and Disease Activity in Rheumatoid Arthritis
Katherine Bracamontes¹, David Kellner², Lucia Chen³, David Elashoff⁴, Jenny Brook⁵ and Veena Ranganath², ¹Division of Internal Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, CA, ³UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, CA, ⁴UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, ⁵UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, CA
Background/Purpose: In women, rheumatoid arthritis (RA) commonly presents around menopause, a timing thought to be influenced by the decline of estrogen and progesterone. However, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].